While the world obsessed over GLP-1 drugs making people slim, Akums quietly pumped out 1,000+ DCGI approvals like a Bollywood sequel factory. Their R&D team seems to file patents the way Indians file RTIs—constantly. With ₹1,500+ crore cash surplus and a European contract advance already pocketed, Akums is sitting on pharma dry powder that can buy more plants than Baba Ramdev has yoga poses. But can this CDMO giant keep margins healthy when API prices keep dieting harder than Bollywood stars before Cannes? Stick around—this ride goes from Haridwar plants to EU dossiers to Nigerian adventures.
2. At a Glance
Revenue ₹1,051 cr (+2.4% YoY, -2.1% QoQ) – Barely grew, like a school kid skipping homework.
EBITDA ₹156 cr (+19% YoY) – Powered by “other income”; core EBITDA only ₹129 cr.
PAT ₹65 cr (+13% YoY) – Still profitable even while APIs sulked.
CDMO revenue ₹813 cr (+4% YoY) – The golden goose keeps laying, albeit smaller eggs.
API revenue ₹45 cr (-35% YoY) – The problem child still bunking class.
Cash Surplus ₹1,518 cr – Sitting prettier than most NBFCs.
3. Management’s Key Commentary
Sandeep Jain (MD): “We hit 1,000 DCGI approvals; 27 this quarter alone.” (Translation: Our R&D team doesn’t sleep, they just file forms.)
On Patents: “Filed 24 new patents and got approval for triple-layered tablets.” (Translation: We’re now layering pills like lasagna.)
On Europe: “First dossier approval for Rivaroxaban; €100m advance received.” (Translation: Europe basically prepaid us like Zomato cash-on-delivery.)
CFO Sumeet Sood: “EBITDA margin expanded 208 bps YoY.” (Translation: Thank you, interest income, for playing hero this quarter.)
On APIs: “Losses halved vs last year.” (Translation: Still bleeding, just less blood this time.)
On Trade Generics: “We’re consolidating, gradually exiting non-performing units.” (Translation: Cleaning up our own house, not just India’s pharma shelves.)
On Jammu Plant: “CAPEX starts late FY26, go-live by March ’27.” (Translation: Pharma factory opening is the new temple inauguration.)
4. Numbers Decoded
Metric
Value (Q1 FY26)
YoY Change
One-Line Analysis
Revenue – The Mixed Bag
₹1,051 cr
+2.4%
Growth slower than a chemist’s queue on Monday.
EBITDA – The Inflated Pill
₹156 cr
+19%
Boosted by interest; true strength lies at ₹129 cr.
